The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced the much-anticipated release of their updated guideline for molecular testing and targeted therapies in lung cancer. The work of these three leading medical societies, updates their 2013 evidence-based guidelines.
Published first online on January 23, the “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors,” makes revisions to standards for the molecular analysis of lung cancers for test results that reflect advances in understanding of lung cancer and the increase in available molecularly-targeted therapies.
“Several factors influenced this update, which builds on the guidance we set forth in 2013,” said Neal Lindeman, MD, director of Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor of Pathology at Harvard Medical School in Boston, and AMP member. “Clinical practice guidelines must continually assess new evidence as it accumulates and consider new testing technologies as they emerge,” he said in a statement.
According to the IASLC press release, the updated guideline "strengthens or reaffirms" the majority of recommendations included in the 2013 guideline and recommends testing for some new genes.
View resources from CAP, IASLC, and AMP to help pathologists and oncologists review and implement the guidelines (includes a summary of recommendations, teaching presention, and FAQs).
Posted 1/25/2018
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
